- Home
- LRE vs CVKD Comparison
LRE vs CVKD Comparison
Compare LRE & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRE | CVKD |
|---|---|---|
| Founded | 2001 | 2022 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 17.3M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LRE | CVKD |
|---|---|---|
| Price | $1.30 | $4.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 21.1K | ★ 44.9K |
| Earning Date | 07-30-2015 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $4.91 |
| 52 Week High | $2.86 | $19.03 |
Technical Indicators
Market Signals| Indicator | LRE | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 46.48 | 27.71 |
| Support Level | $1.20 | N/A |
| Resistance Level | $1.43 | $14.21 |
| Average True Range (ATR) | 0.09 | 0.63 |
| MACD | -0.00 | -0.30 |
| Stochastic Oscillator | 15.04 | 3.96 |
Price Performance
Historical ComparisonAbout LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.